A new technology could prevent most breast implant rejections. So far, more than a quarter of all breast implants must be removed within four years, because neighboring tissues develop a rigid envelope of fibrous tissue to protect themselves from the foreign body.

New research shows that the health of the city's most deprived residents could be impaired before they are even born.

Doctors should feel more confident in recommending lithium for people with bipolar disorder, say Oxford University researchers who have reviewed the evidence on possible side-effects of the drug.

Phase III results showed 54% reduction in risk of recurrence and 55% reduction in risk of death after three years' adjuvant Glivec in adults with KIT+ GIST - Approval builds on vast experience with Glivec, first approved 10 years ago for

RNA profiling and ChIP-Sequencing reveal that PTF1a stabilizes pancreas progenitor identity via the control of MNX1/HLXB9 and a network of other transcription factors.

Fourth quarter sales rose 5% while core operating income grew 17% in constant currencies (cc); full year sales up 12% cc and core operating income up 16% cc - Core operating income grew 12% (+17% cc) to USD 3.6 billion in the fourth qua

Research has taken us a step closer to breeding hardier crops that can better adapt to different environmental conditions and fight off attack from parasites.

Scientists are developing a test that will help identify patients who will benefit from a new breast cancer treatment, thanks to a research grant worth almost £180,000 from Breast Cancer Campaign.

Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+? (Review) - Sirtuin 1 (SIRT1) is an evolutionarily conserved NAD+-dependent deacetylase that is at the pinnacle of metabolic control, all the way from yeast to humans.

Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash - Roche , a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, announced today that it has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc.

Roche responds to adoption of shareholder rights plan by Illumina Board of Directors - Roche today responded to an announcement from Illumina, Inc.

The group of Carl Petersen (LSENS - Laboratoire de traitement sensoriel ) investigated the impact of thalamus on ongoing cortical activity in the awake, behaving mouse.